Abstract:

Depot-Medroxyl-Progesterone-Acetate-Subcutaneous/Self Injection (DMPA-SC/SI) is an intentional approach used by the Nigerian government to improve the coverage rate of contraceptives method-mix. In this study, the knowledge, practice, and determinants of use of DMPA-SC/SI among women in North-Central and South-West, Nigeria, was assessed. A cross-sectional health facility study was conducted across four Nigerian states. Structured pretested questionnaires were used to elicit information from 844 women within reproductive age. Twenty focused group discussions and 40 In-depth interviews (IDIs). Descriptive statistics were used to analyze the characteristics of the women. Multivariate logistic regression was used to examine the determinants of the current use of DMPA-SC /SI. Statistical analyses were set at 5%. Recorded voices were transcribed in full and analyzed using literary methods. About 89.5% of respondents reported ever heard family planning; 97.6% reported heard DMPA-SC; 83.2% reported ever use family planning; 95.7% reported current use of family planning; 94.3% reported ever use DMPA-SC, and 46.5% reported ever use DMPA-SC/SI. The reason for the use of DMPA-SC/SI was because it was easy to use, effective and self-administered. The factors that discourage women from using DMPA-SC/SI were mainly fears associated with side effects, for and fear of SI-self-injury. The logistic regression results showed that those residing in a rural part of the country were less likely to use DMPA-SC/SI. The government should scale up this model nationally, including rural and hard-to-reach communities with public awareness programmes, public sensitization, and refresher training to improve on Provider’s counselling skills.

Keywords: Knowledge, Practice, Self-injectable contraceptive.

References:

[1] Moon TD, Okoth V, Starnes JR, et al. Determinants of modern contraceptive prevalence and unplanned pregnancies in Migori County, Kenya: results of a cross-sectional household survey. Afr J Reprod Health 2021; 25: 29.

[2] Mochache V, Lakhani A, El-Busaidy H, et al. Pattern and determinants of contraceptive usage among women of reproductive age from the Digo community residing in Kwale, Kenya: results from a cross-sectional household survey. BMC Women’s Health 2018; 18: 10.

[3] Ameyaw EK, Budu E, Sambah F, et al. Prevalence and determinants of unintended pregnancy in sub-Saharan Africa: A multi-country analysis of demographic and health surveys. PLoS ONE 2019; 14: e0220970.

[4] United Nations Department of Economic and Social Affairs. Family Planning and the 2030 Agenda for Sustainable Development (Data Booklet). United Nations. Epub ahead of print September 20, 2019. DOI: 10.18356/e154e49d-en.

[5] Dasgupta ANZ, Wheldon M, Kantorova V, et al. Progress in Family Planning: Did the Millennium Development Goals Make a Difference? In: Population Association of America. Austin: Population Division, United Nations, Department of Economic and Social Affairs, 2019, p. 10.

[6] Ba DM, Ssentongo P, Agbese E, et al. Prevalence and predictors of contraceptive use among women of reproductive age in 17 sub-Saharan African countries: A large population-based study. Sex Reprod Health c 2019; 21: 26–32.

[7] Prata N, Weidert K, Fraser A, et al. Meeting Rural Demand: A Case for Combining Community-Based Distribution and Social Marketing of Injectable Contraceptives in Tigray, Ethiopia. PLoS ONE 2013; 8: e68794.

[8] Sileo KM, Wanyenze RK, Lule H, et al. Determinants of family planning service uptake and use of contraceptives among postpartum women in rural Uganda. Int J Public Health 2015; 60: 987–997.

[9] National Population Commission (NPC) [Nigeria] and ICF. 2019. Nigeria Demographic and Health Survey 2018, https://www.dhsprogram.com/pubs/pdf/FR359/FR359 pdf (2019, accessed October 24, 2020).

[10] Total Fertility Rate in Nigeria Decreases Slightly as the Contraceptive Prevalence Rate Increases | JHU - Advance Family Planning, https://www.advancefamilyplanning.org/total-fertility-rate-nigeria-decreases-slightly-contraceptive-prevalence-rate-increases (accessed July 10, 2021).

[11] National Population Commission. Nigeria Demographic and Health Survey 2018. Key Indicators Report, Nigeria: The DHS Program ICF Rockville, Maryland, USA.

[12] Cover J, Namagembe A, Tumusiime J, et al. Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda. Contraception 2018; 98: 383–388.

[13] Kohn JE, Simons HR, Della Badia L, et al. Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood. Contraception 2018; 97: 198–204.

[14] Liu J, Shen J, Diamond-Smith N. Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects. Contraception 2018; 98: 430–437.

[15] Ahuru RR. The influence of women empowerment on maternal and childcare use in Nigeria. Int J Healthc Manag 2019; 1–10.

[16] Cochran WG. Professor of Statistics, Emeritus Harvard University. 10.

[17] Yaya S, Uthman OA, Ekholuenetale M, et al. Women empowerment as an enabling factor of contraceptive use in sub-Saharan Africa: a multilevel analysis of cross-sectional surveys of 32 countries. Reprod Health 2018; 15: 214.

[18] Aliyu AA, Dahiru T. Reproductive Health and Family Planning Services in Africa: Looking beyond Individual and Household Factors. In: Amarin Z, Abduljabbar H (eds) Family Planning and Reproductive Health. IntechOpen. Epub ahead of print December 2, 2020. DOI: 10.5772/intechopen.92138.

[19] Solanke BL. Factors influencing contraceptive use and non-use among women of advanced reproductive age in Nigeria. J Health Popul Nutr 2017; 36: 1.

[20] Adebowale SA, Ajiboye BV, Arulogun O. Patterns and Correlates of Condom Use among Unmarried Male Youths in Nigeria: NDHS 2008. Afr J Reprod Health 2017; 17: 149–159.

[21] Kanwal N, Muttappallymyalil J, Al-Sharbatti S, et al. Contraceptive Utilisation Among Mothers of Reproductive Age in Ajman, United Arab Emirates. Sultan Qaboos Univ Med J 2017; 17: e50–e58.

[22] Olugbenga-Bello AI, Adebimpe WO, Akande RO, et al. Health risk behaviors and sexual initiation among in-school adolescents in rural communities in southwestern Nigeria. Int J Adolesc Med Health 2014; 26: 503–510.

[23] Burke HM, Chen M, Buluzi M, et al. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial. Lancet Glob Health 2018; 6: e568–e578.

[24] Ezegwui H, Ikeako L, Obiora-Okafor N. The use of Depot Medroxyprogesterone Acetate (DMPA) Injectable Contraceptive in Enugu, Nigeria. Niger J Med 2012; 21: 6.

[25] Prabhakaran S, Sweet A. Self-administration of subcutaneous depot medroxyprogesterone acetate for
contraception: feasibility and acceptability. Contraception 2012; 85: 453–457.

[26] Beasley A, White KO, Cremers S, et al. Randomized clinical trial of self-versus clinical administration of subcutaneous depot medroxyprogesterone acetate. Contraception 2014; 89: 352–356.

[27] Mairiga AG, Kyari O, Audu B, et al. Socio-clinical characteristics of modern contraceptives users at the University of Maiduguri Teaching Hospital. Niger J Clin Pract 2007; 10: 152-155.

[28] Abasiattai A, Udoma E, Ukeme E. Depot medroxyprogesterone injectable contraception at the University of Uyo Teaching Hospital, Uyo. Ann Afr Med 2010; 9: 81.

[29] Ross J, Hardee K. Access to contraceptive methods and prevalence of use. J Biosoc Sci 2013; 45: 761–778.

[30] Ross J, Keesbury J, Hardee K. Trends in the Contraceptive Method Mix in Low- and Middle-Income Countries: Analysis Using a New “Average Deviation” Measure. Glob Health Sci Pract 2015; 3: 34–55.

[31] Ross JA, Agwanda AT. Increased use of injectable contraception in sub-Saharan Africa. Afr J Reprod Health 2012; 16: 68–80.